1. Sheng Mai Yin shows anti-fatigue, anti-hypoxia and cardioprotective potential in an experimental joint model of fatigue and acute myocardial infarction.
- Author
-
Guo, Hao, Li, Pengqi, Zhao, Jun, Xin, Qiqi, Miao, Yu, Li, Li, Li, Xin, Wang, Shanglong, Mo, Hui, Zeng, Li, Ju, Zhenyu, Liu, Zimin, Shen, Xiaoxu, and Cong, Weihong
- Subjects
- *
HERBAL medicine , *IN vivo studies , *MYOCARDIUM , *HEART cells , *ANIMAL experimentation , *AUTOPHAGY , *MYOCARDIAL infarction , *APOPTOSIS , *BIOINFORMATICS , *RATS , *MITOCHONDRIA , *OXIDATIVE stress , *CELLULAR signal transduction , *FATIGUE (Physiology) , *PHARMACEUTICAL chemistry , *HYPOXEMIA , *CHINESE medicine , *CARDIOTONIC agents , *MICE , *PHARMACODYNAMICS , *DRUG administration , *DRUG dosage - Abstract
Cardiovascular disease (CVD) and fatigue are two common diseases endangering human life and health that may interact and reinforce one another. Myocardial infarction survivors frequently experience fatigue, and acute myocardial infarction (AMI) is one of the most common cardiovascular diseases that cause fatigue-induced sudden death. Sheng Mai Yin (SMY), a Chinese medicine prescription, is traditionally used for the treatment of diabetes and cardiovascular disease, and has been demonstrated to reduce fatigue and safeguard cardiac function. This study aims to investigate the effects and underlying mechanisms of SMY in treating fatigue and AMI. The pharmacological mechanisms of SMY in treating fatigue and AMI were predicted by bioinformatics and network pharmacology methods. After administering SMY at high, medium and low doses, the swimming time to exhaustion, hemoglobin level, serological parameters and hypoxia tolerance time were detected in C57BL/6N mice, and the left ventricular ejection fractions (LVEF), left ventricular fractional shortening (LVFS), grasp strength, cardiac histopathology, serological parameters and the expression of PINK1 and Parkin proteins were examined in Wistar rats. 371 core targets for SMY and 282 disease targets for fatigue and AMI were obtained using bioinformatics and network pharmacology methods. Enrichment analysis of target genes revealed that SMY might interfere with fatigue and AMI through biological processes such as mitochondrial autophagy, apoptosis, and oxidative stress. For in vivo experiments, SMY showed significant anti-fatigue and hypoxia tolerance effects in mice; It also improved the cardiac function and grasp strength, decreased their cardiac index, myocardial injury and fibrosis degree, and induced serological parameters levels and the expression of PTEN-induced putative kinase 1 (PINK1) and Parkin proteins in myocardium, suggesting that SMY may exert cardioprotective effects in a joint rat model of fatigue and AMI by inhibiting excessive mitochondrial autophagy. This study revealed the anti-fatigue, anti-hypoxia and cardioprotective effects of SMY in a joint model of fatigue-AMI, and the pharmacological mechanism may be related to the inhibition of mitochondrial autophagy in cardiomyocytes through the PINK1/Parkin pathway. The discoveries may provide new ideas for the mechanism study of traditional Chinese medicine, especially complex prescriptions, in treating fatigue and AMI. [Display omitted] • Fatigue and acute myocardial infarction may be related to apoptotic process. • Sheng Mai Yin reduced fatigue, hypoxia and heart damage in mice and rats. • Sheng Mai Yin may suppress PINK1 and Parkin expression in the mitochondrial autophagy of myocardium. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF